Search Results for “biotechnology” – Page 24 – media

Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases

Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing.
- Source: silversteinfoundation.orgl
- 658
- March 13, 2018
financing gene Market Views Parkinson’s disease
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets

Vividion to receive $101 million in upfront payment, including equity investment Collaboration utilizes Vividion's unique proteome-wide ligand and target discovery platform
- Source: prnewswire
- 450
- March 7, 2018
Celgene
Galera Therapeutics Receives FDA Breakthrough Therapy Designation for GC4419 for the Reduction of Severe Oral Mucositis

Designation Based on Positive Results of Phase 2b Trial of GC4419 Severe Oral Mucositis Affects 70 Percent of Head & Neck Cancer Patients Receiving Radiotherapy
- Source: 4-traders
- 467
- March 2, 2018
FDA New Approvals severe oral mucositis SOM
Viela Bio Spins Out of MedImmune; Raises Up to $250 Million in Series A Financing, 6 Dimensions Capital Leads Investment

Viela Bio announced today that it has incorporated as an independent, inflammation - and autoimmunity - focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca. Viela Bio will primarily focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of the diseases.
- Source: finance.yahoo
- 475
- March 1, 2018
autoimmunity inflammation Market Views
Carewave Medical raising cash for pain relieving wearable, with support from big biotech names

Medical device company Carewave Medical is looking to raise $1 million to support its wearable pain relief technology, according to an SEC filing.
- Source: GeekWire
- 706
- February 28, 2018
healthcare technologies and innovations medical device medtech Researches
How Precision Medicine is breaking off Chokehold on Healthcare with Big Data

Big data is showering its miraculous effects on a range of industries. And the healthcare industry is not left out of the bandwagon. Precision medicine is at the brink of a revolution in individualizing treatment, and healthcare professionals are devising ways to prevent and treat diseases with granularity down to a single patient’s genome.
- Source: dexlabanalytics
- 538
- February 23, 2018
big data healthcare Researches
FDA Clears UC Davis Startup’s Polymer to Aid Bone Regrowth

Molecular Matrix Inc. invented a synthetic bone void filler, Osteo-P, that can help injured bones regrow.
- Source: ODT
- 605
- February 1, 2018
bone FDA medical device
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 606
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMS) (BMY) under the license and collaboration agreement between the companies established in 2015. The milestone was triggered by initiation of a multi-arm Phase 2 clinical trial (NCT03336216), sponsored by Bristol-Myers Squibb Company, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. “Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.” The Phase 2 trial is expected to enroll approximately 160 ...
- Source: finance.yahoo
- 552
- January 31, 2018
Bristol-Myers Squibb cabiralizumab Opdivo
Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, today announced the completion of a $58 million Series A financing. This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline. Polaris Partners, the founding investor that provided the initial seed funding, co-led the Series A financing along with Versant Ventures and Roche Venture Fund. SR One and BioInnovation Capital also participated in the round.
- Source: finance.yahoo
- 898
- January 22, 2018
antibody Company Insight immunomodulation

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.